ANIK

Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026

Anika Therapeutics to announce Q2 2026 results with near-term ANIK catalyst

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Anika will report Q2 2026 results before the market on July 29, with a conference call at 8:30 a.m. ET. Investors will parse headline results and any commentary on Osteoarthritis and Regenerative Solutions, which could set near-term momentum for ANIK depending on the beat or guidance.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>ANIK to release Q2 2026 results before market July 29.</li><li>Conference call at 8:30 a.m. ET; ID 60388.</li><li>Live webcast and investor materials on Anika IR site.</li><li>Focus areas: Osteoarthritis Pain Management and Regenerative Solutions.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Anika Therapeutics, Inc. (ANIK)</strong>: Upcoming Q2 2026 results; near-term stock volatility based on headline numbers and guidance.</li></ul>
  </section>

  <section data-block="category">
    <h3>Earnings</h3>
    <p>Earnings-related event for a small-cap biopharma/ortho company; the results timing creates near-term stock volatility as investors gauge performance and guidance.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Q2 results timing could prompt near-term ANIK price movement depending on headlines.</li><li>Positive guidance would likely spark a short-term rally; downside risk on misses.</li><li>Market focus on orthopedics market momentum and reimbursement dynamics.</li><li>Event could create short-term volatility around July 29.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Q2 2026 results release date: July 29, 2026.</li><li>Conference call time: 8:30 a.m. ET.</li><li>Domestic toll-free: 1-800-717-1738; International: 1-646-307-1865.</li><li>Conference ID: 60388.</li><li>Investor relations: www.anika.com.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Positive Q2 results or guidance could spark a near-term rally in ANIK within days to weeks.</p>
  </section>
</section>


<article>
  <section>
    <h2>ANIK to Issue Second Quarter 2026 Financial Results; Conference Call Planned</h2>
    <p>Anika Therapeutics, Inc. (<strong>NASDAQ: ANIK</strong>), a global joint preservation company in early intervention orthopedics, announced today that it will issue its second quarter 2026 financial results before the opening of the market on Wednesday, July 29, 2026, followed by a conference call at <strong>8:30 a.m. ET</strong> to discuss its results and business highlights. This press release outlines the company's second quarter 2026 earnings results and business highlights.</p>
  </section>

  <section>
    <h2>Conference Call Access & Materials</h2>
    <ul>
      <li><strong>Dial-in numbers:</strong> <strong>1-800-717-1738</strong> (toll-free domestic) or <strong>1-646-307-1865</strong> (international) and providing the conference ID number <strong>60388</strong>.</li>
      <li>A live audio webcast and accompanying presentation materials will be available in the <em>Investor Relations</em> section of Anika's website, <strong>www.anika.com</strong>.</li>
      <li>The call will be archived and accessible on the same website shortly after its conclusion.</li>
    </ul>
  </section>

  <section>
    <h2>About Anika</h2>
    <p>Anika Therapeutics, Inc. (<strong>NASDAQ: ANIK</strong>), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management and Regenerative Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit <strong>www.anika.com</strong>.</p>
    <p>ANIKA, ANIKA THERAPEUTICS and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.</p>
  </section>

  <section>
    <h2>Investor Inquiries</h2>
    <p>Anika Therapeutics, Inc.</p>
    <p>Matt Hall, <strong>781-457-9554</strong></p>
    <p>Executive Director, Corporate Development and Investor Relations</p>
    <p><a href="https://www.globenewswire.com/Tracker?data=_WxpmQaLgyXaZfz3o7OuR04l50iA83zWQjMKuTU27ui0RC_shggSVZGphE9llxcaP10lEN8_-ZnzRo6D0gMLXa_6-s5GGbgqY3YqXgQCLY-lQI7-ZeQ6Sbw0ddJ44zvo" rel="nofollow" target="_blank">investorrelations@anika.com</a></p>
  </section>
</article>

Anika will report Q2 2026 results before the market on July 29, with a conference call at 8:30 a.m. ET. Investors will parse headline results and any commentary on Osteoarthritis and Regenerative Solutions, which could set near-term momentum for ANIK depending on the beat or guidance.

Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Earnings

Related News